EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

Or Michaeli, Ishai Luz iD, Maayan Vatarescu, Tal Manko, Noam Weizman, Yevgeniya Korotinsky, Alexandra Tsitrina, Alex Braiman, Lior Arazi, Tomer Cooks iD

Cell Death & Disease · 2024

DOI: 10.1038/s41419-024-06830-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Death & Disease, 2024. Verfasst von Or Michaeli und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel. Hauptthemen laut MEDLINE: Alpha Particles, Tumor Suppressor Protein p53, Radiation-Sensitizing Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Cancer Association (ICA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiation therapy (RT) remains a common treatment for cancer patients worldwide, despite the development of targeted biological compounds and immunotherapeutic drugs. The challenge in RT lies in delivering a lethal dose to the cancerous site while sparing the surrounding healthy tissues. Low linear energy transfer (low-LET) and high linear energy transfer (high-LET) radiations have distinct effects on cells. High-LET radiation, such as alpha particles, induces clustered DNA double-strand breaks (DSBs), potentially inducing cell death more effectively. However, due to limited range, alpha-particle therapies have been restricted. In human cancer, mutations in TP53 (encoding for the p53 tumor suppressor) are the most common genetic alteration. It was previously reported that cells carrying wild-type (WT) p53 exhibit accelerated senescence and significant rates of apoptosis in response to RT, whereas cells harboring mutant p53 (mutp53) do not. This study investigated the combination of the alpha-emitting atoms RT based on internal Radium-224 ( 224 Ra) sources and systemic APR-246 (a p53 reactivating compound) to treat tumors with mutant p53. Cellular models of colorectal cancer (CRC) or pancreatic ductal adenocarcinoma (PDAC) harboring mutant p53, were exposed to alpha particles, and tumor xenografts with mutant p53 were treated using 224 Ra source and APR-246. Effects on cell survival and tumor growth, were assessed. The spread of alpha emitters in tumors was also evaluated as well as the spatial distribution of apoptosis within the treated tumors. We show that mutant p53 cancer cells exhibit radio-sensitivity to alpha particles in vitro and to alpha-particles-based RT in vivo. APR-246 treatment enhanced sensitivity to alpha radiation, leading to reduced tumor growth and increased rates of tumor eradication. Combining alpha-particles-based RT with p53 restoration via APR-246 triggered cell death, resulting in improved therapeutic outcomes. Further preclinical and clinical studies are needed to provide a promising approach for improving treatment outcomes in patients with mutant p53 tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha ParticlesTumor Suppressor Protein p53Radiation-Sensitizing AgentsHumansAnimalsMiceMutationQuinuclidinesCell Line, TumorMice, NudeXenograft Model Antitumor AssaysApoptosisNeoplasms

Substanzen

Tumor Suppressor Protein p53eprenetapoptRadiation-Sensitizing AgentsQuinuclidinesTP53 protein, human

Autor:innen und Institutionen

  • The Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel.
  • Translational Research Laboratory, Alpha Tau Medical, Jerusalem, Israel.
  • Unit of Nuclear Engineering, Faculty of Engineering Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • The Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel. cooks@bgu.ac.il.

ORCID-Profile: Ishai Luz, Tomer Cooks

Förderung

  • Israel Cancer Association (ICA)

Zitieren

APA

Michaeli, O., Luz, I., Vatarescu, M., Manko, T., Weizman, N., Korotinsky, Y., Tsitrina, A., Braiman, A., Arazi, L., & Cooks, T. (2024). APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy. Cell Death & Disease. https://doi.org/10.1038/s41419-024-06830-3

Vancouver

Michaeli O, Luz I, Vatarescu M, Manko T, Weizman N, Korotinsky Y, et al. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy. Cell Death & Disease. 2024. doi:10.1038/s41419-024-06830-3

BibTeX
@article{Michaeli2024,
  author = {Michaeli, Or and Luz, Ishai and Vatarescu, Maayan and Manko, Tal and Weizman, Noam and Korotinsky, Yevgeniya and Tsitrina, Alexandra and Braiman, Alex and Arazi, Lior and Cooks, Tomer},
  title = {APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy},
  journal = {Cell Death & Disease},
  year = {2024},
  doi = {10.1038/s41419-024-06830-3}
}
Kostenlos starten →